Literature DB >> 10816621

Treatment of experimentally induced caval thrombosis with oral low molecular weight heparin and delivery agent in a porcine model of deep venous thrombosis.

K Salartash1, M Lepore, M D Gonze, A Leone-Bay, R Baughman, W C Sternbergh, J C Bowen, S R Money.   

Abstract

OBJECTIVE: This experiment evaluated enterally administered low molecular weight heparin (LMWH) combined with sodium N-[10-(2-hydroxybenzoyl)amino] decanoate (SNAD) for the treatment of induced venous thrombosis. SUMMARY BACKGROUND DATA: SNAD is a delivery agent that potentiates the gastrointestinal absorption of LMWH.
METHODS: Forty female pigs were equally assigned to four groups: control (saline); enteral LMWH, 2,000 IU/kg; enteral SNAD, 50 mg/kg; and enteral LMWH, 2,000 IU/kg and SNAD, 50 mg/kg. Under fluoroscopic guidance, the infrarenal vena cava was occluded with a balloon catheter. Two milliliters of ethanol was injected into the distal vena cava. The inflated balloon catheter remained in situ for 5 days, at which time animals angiographically exhibiting thrombus were randomly assigned to the four groups. Study medications were dosed at 12-hour intervals by means of a gastrostomy tube placed previously. After 7 days of treatment, thrombus was extracted. A separate group of 10 animals was used to measure plasma antifactor Xa levels for 6 hours after enteral dosing of LMWH/SNAD.
RESULTS: The amount of residual thrombus after treatment with enteral LMWH/SNAD was significantly decreased. Antifactor Xa levels were significantly elevated in the LMWH/SNAD group versus baseline.
CONCLUSION: The combination of enterally administered LMWH and SNAD given for 7 days appeared to decrease caval thrombosis in this model of deep vein thrombosis. Enteral LMWH/SNAD effected an increase in plasma levels of antifactor Xa.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10816621      PMCID: PMC1421067          DOI: 10.1097/00000658-200006000-00002

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  12 in total

1.  Low-molecular-weight heparin in the emergency department treatment of venous thromboembolism.

Authors:  G D Innes; E C Dillon; A Holmes
Journal:  J Emerg Med       Date:  1997 Jul-Aug       Impact factor: 1.484

2.  Enoxaparin, a low-molecular-weight heparin suppresses prothrombin activation more effectively than unfractionated heparin in patients treated for venous thromboembolism.

Authors:  A B Grosset; T E Spiro; J Beynon; G M Rodgers
Journal:  Thromb Res       Date:  1997-06-01       Impact factor: 3.944

3.  Induced thrombosis in the pig inferior vena cava: a model of deep venous thrombosis.

Authors:  J Hosaka; S Roy; K Kvernebo; I Enge; F Laerum
Journal:  J Vasc Interv Radiol       Date:  1996 May-Jun       Impact factor: 3.464

4.  Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection.

Authors:  P S Wells; M J Kovacs; J Bormanis; M A Forgie; D Goudie; B Morrow; J Kovacs
Journal:  Arch Intern Med       Date:  1998-09-14

Review 5.  Low-molecular-weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results.

Authors:  M Crowther; J Hirsh
Journal:  Semin Thromb Hemost       Date:  1997       Impact factor: 4.180

6.  Oral low-molecular weight heparin and delivery agent prevents jugular venous thrombosis in the rat.

Authors:  K Salartash; M D Gonze; A Leone-Bay; R Baughman; W C Sternbergh; S R Money
Journal:  J Vasc Surg       Date:  1999-09       Impact factor: 4.268

Review 7.  Low molecular weight heparins for venous thromboembolism.

Authors: 
Journal:  Drug Ther Bull       Date:  1998-04

8.  Home treatment of deep vein thrombosis: a two-years experience of a single institution.

Authors:  E Grau; E Real; E Pastor; V Viciano; J Aguiló
Journal:  Haematologica       Date:  1998-05       Impact factor: 9.941

9.  A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.

Authors:  M Levine; M Gent; J Hirsh; J Leclerc; D Anderson; J Weitz; J Ginsberg; A G Turpie; C Demers; M Kovacs
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

Review 10.  Unfractionated versus low-molecular-weight heparin in the treatment of venous thromboembolism.

Authors:  H Bounameaux
Journal:  Vasc Med       Date:  1998       Impact factor: 3.239

View more
  9 in total

1.  Enhancement of the intestinal absorption of low molecular weight heparin (LMWH) in rats and pigs using Carbopol 934P.

Authors:  M Thanou; J C Verhoef; M T Nihot; J H Verheijden; H E Junginger
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

2.  Oral delivery of low-molecular-weight heparin using sodium caprate as absorption enhancer reaches therapeutic levels.

Authors:  Nusrat A Motlekar; Kalkunte S Srivenugopal; Mitchell S Wachtel; Bi-Botti C Youan
Journal:  J Drug Target       Date:  2005-12       Impact factor: 5.121

3.  The new heparins.

Authors:  Michael S Conners; Samuel R Money
Journal:  Ochsner J       Date:  2002

4.  Antiangiogenic activity of orally absorbable heparin derivative in different types of cancer cells.

Authors:  Dong Yun Lee; Sung Won Lee; Sang Kyoon Kim; Myungjin Lee; Hyo Won Chang; Hyun Tae Moon; Youngro Byun; Sang Yoon Kim
Journal:  Pharm Res       Date:  2009-10-15       Impact factor: 4.200

5.  Tissue distribution of [14C]sucrose octasulfate following oral administration to rats.

Authors:  Linda M Hiebert; Sandra M Wice; Tidly Ping; Ronald E Hileman; Tfilay Polat; Robert J Linhardt
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

6.  Oral heparin: status review.

Authors:  Ehud Arbit; Michael Goldberg; Isabel Gomez-Orellana; Shingai Majuru
Journal:  Thromb J       Date:  2006-05-10

Review 7.  Heparin and Its Derivatives: Challenges and Advances in Therapeutic Biomolecules.

Authors:  Nipa Banik; Seong-Bin Yang; Tae-Bong Kang; Ji-Hong Lim; Jooho Park
Journal:  Int J Mol Sci       Date:  2021-09-29       Impact factor: 5.923

8.  A case of hepatic cyst-induced inferior vena cava thrombosis.

Authors:  Jaecheol Moon; Dahee Heo; Sanghoon Han
Journal:  Pak J Med Sci       Date:  2014-05       Impact factor: 1.088

Review 9.  Advanced delivery strategies facilitating oral absorption of heparins.

Authors:  Guihua Fang; Bo Tang
Journal:  Asian J Pharm Sci       Date:  2020-01-09       Impact factor: 6.598

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.